Affordable Access

deepdyve-link
Publisher Website

Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part I: Traditional agents.

Authors
  • Farmakidis, Constantine1
  • Dimachkie, Mazen M1
  • Pasnoor, Mamatha1
  • Barohn, Richard J1
  • 1 Neurology Department, University of Kansas Medical Center, Kansas City, Kansas.
Type
Published Article
Journal
Muscle & Nerve
Publisher
Wiley (John Wiley & Sons)
Publication Date
Jan 01, 2020
Volume
61
Issue
1
Pages
5–16
Identifiers
DOI: 10.1002/mus.26708
PMID: 31509257
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Immunosuppressive and immunomodulatory therapies have had a major effect on the treatment of immune-mediated neuromuscular diseases. After the landmark introduction of synthetic corticosteroids, other therapies have become available, including plasma exchange (PLEX), immunoglobulin G (IgG), and steroid-sparing immunosuppressive drugs. More recently, novel biologically derived and antigen-specific pharmaceuticals have entered neuromuscular practice. Various levels of evidence guide the use of these treatments. This article reviews current immune-based therapies in neuromuscular diseases and is divided into two parts. Part I provides an update on the evidence and use of traditional therapies, such as corticosteroids, PLEX, intravenously delivered IgG (IVIG), and steroid-sparing immunosuppressive drugs. Part II focuses on the recently US Food and Drug Administration-approved therapies eculizumab and subcutaneous IgG (SCIG), the current indications for rituximab in neuromuscular disease, and on novel immunosuppressive therapeutic approaches under development. © 2019 Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times